Background: We have previously demonstrated an association between elevated
total plasma homocysteine levels and restenosis after percutaneous coronar
y angioplasty. We designed this study to evaluate the effect of lowering pl
asma homocysteine levels on restenosis after coronary angioplasty.
Methods: A combination of folic acid (1 mg), vitamin B(sub 12) (400 microg)
, and pyridoxine (10 mg) - referred to as folate treatment - or placebo was
administered to 205 patients (mean [+/-SD] age, 61+/-11 years) for six mon
ths after successful coronary angioplasty in a prospective, double-blind, r
andomized trial. The primary end point was restenosis within six months as
assessed by quantitative coronary angiography. The secondary end point was
a composite of major adverse cardiac events.
Results: Base-line characteristics and initial angiographic results after c
oronary angioplasty were similar in the two study groups. Folate treatment
significantly lowered plasma homocysteine levels from 11.1+/-4.3 to 7.2+/-2
.4 micromol per liter (P<0.001). At follow-up, the minimal luminal diameter
was significantly larger in the group assigned to folate treatment (1.72+/
-0.76 vs. 1.45+/-0.88 mm, P=0.02), and the degree of stenosis was less seve
re (39.9+/-20.3 percent vs. 48.2+/-28.3 percent, P=0.01). The rate of reste
nosis was significantly lower in patients assigned to folate treatment (19.
6 percent vs. 37.6 percent, P=0.01), as was the need for revascularization
of the target lesion (10.8 percent vs. 22.3 percent, P=0.047).
Conclusions: Treatment with a combination of folic acid, vitamin B(sub 12),
and pyridoxine significantly reduces homocysteine levels and decreases the
rate of restenosis and the need for revascularization of the target lesion
after coronary angioplasty. This inexpensive treatment, which has minimal
side effects, should be considered as adjunctive therapy for patients under
going coronary angioplasty. (N Engl J Med 2001;345:1593-600.) Copyright (C)
2001 Massachusetts Medical Society.